{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T10:46:10Z","timestamp":1785149170952,"version":"3.55.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.jaad.2015.09.039","type":"journal-article","created":{"date-parts":[[2015,11,11]],"date-time":"2015-11-11T09:15:20Z","timestamp":1447233320000},"page":"363-369","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Thalidomide for the treatment of chronic refractory pruritus"],"prefix":"10.1016","volume":"74","author":[{"given":"Divya","family":"Sharma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn G.","family":"Kwatra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.09.039_bib2","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1056\/NEJM196212062672305","article-title":"The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies","volume":"267","author":"Mellin","year":"1962","journal-title":"N Engl J Med"},{"issue":"NS373","key":"10.1016\/j.jaad.2015.09.039_bib3","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/S1086-5802(16)30221-2","article-title":"Thalidomide. A surprising recovery","author":"Stirling","year":"1997","journal-title":"J Am Pharm Assoc (Wash)"},{"issue":"9","key":"10.1016\/j.jaad.2015.09.039_bib4","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1365-4362.1984.tb05696.x","article-title":"Thalidomide therapy for inflammatory dermatoses","volume":"23","author":"Grosshans","year":"1984","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1440-0960.2002.00608.x","article-title":"Thalidomide in dermatology","volume":"43","author":"Wines","year":"2002","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.09.039_bib6","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM196212132672407","article-title":"The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies","volume":"267","author":"Mellin","year":"1962","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2015.09.039_bib7","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/cpt196563303","article-title":"Thalidomide in the treatment of lepra reactions","volume":"6","author":"Sheskin","year":"1965","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jaad.2015.09.039_bib8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0733-8635(05)70232-1","article-title":"Thalidomide","volume":"19","author":"Radomsky","year":"2001","journal-title":"Dermatol Clin"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib9","first-page":"5","article-title":"H.S., A review of thalidomide's history and current\u00a0dermatological applications","volume":"9","author":"Perri","year":"2003","journal-title":"Dermatol Online J"},{"issue":"6","key":"10.1016\/j.jaad.2015.09.039_bib10","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","article-title":"Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses","volume":"35","author":"Tseng","year":"1996","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib11","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1085-5629(98)80019-9","article-title":"Thalidomide and its impact in dermatology","volume":"17","author":"Stirling","year":"1998","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jaad.2015.09.039_bib12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/tera.1420160113","article-title":"Thalidomide embryopathy","volume":"16","author":"McBride","year":"1977","journal-title":"Teratology"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib13","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.det.2010.03.003","article-title":"Innovative uses of thalidomide","volume":"28","author":"Chen","year":"2010","journal-title":"Dermatol Clin"},{"issue":"10","key":"10.1016\/j.jaad.2015.09.039_bib14","first-page":"1355","article-title":"Thalidomide is distributed into human semen after oral dosing","volume":"29","author":"Teo","year":"2001","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib15","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/(SICI)1096-9926(199609)54:3<126::AID-TERA2>3.0.CO;2-1","article-title":"Mesonephros has a role\u00a0in limb development and is related to thalidomide embryopathy","volume":"54","author":"Smith","year":"1996","journal-title":"Teratology"},{"issue":"9","key":"10.1016\/j.jaad.2015.09.039_bib16","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","article-title":"Thalidomide is an inhibitor of angiogenesis","volume":"91","author":"D'Amato","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib17","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1177\/2040620711413165","article-title":"The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development","volume":"2","author":"Rehman","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jaad.2015.09.039_bib18","unstructured":"Thalidomide. Lexi-Comp Online. In Lexi-Drugs [Internet]. Hudson, OH: Lexi-Comp, Inc. July 26, 2015."},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib19","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1523-1747.2002.19502.x","article-title":"Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients","volume":"119","author":"Bastuji-Garin","year":"2002","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib20","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial","year":"2003","journal-title":"J Support Oncol"},{"issue":"12","key":"10.1016\/j.jaad.2015.09.039_bib21","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1212\/01.WNL.0000131766.90137.DF","article-title":"Thalidomide neuropathy: too much or too long?","volume":"62","author":"Apfel","year":"2004","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.jaad.2015.09.039_bib22","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1212\/WNL.62.12.2291","article-title":"Thalidomide sensory neurotoxicity: a clinical\u00a0and neurophysiologic study","volume":"62","author":"Caveletti","year":"2004","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib23","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2133.1985.tb02323.x","article-title":"Development of polyneuropathy during thalidomide therapy","volume":"112","author":"Wulff","year":"1985","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib24","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archderm.1984.01650390060012","article-title":"Thalidomide neurotoxicity","volume":"120","author":"Clemmensen","year":"1984","journal-title":"Arch Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2015.09.039_bib25","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/jnnp.31.6.543","article-title":"Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study","volume":"31","author":"Fullerton","year":"1968","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib26","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.jaad.2015.01.002","article-title":"Review of thalidomide use in the\u00a0pediatric population","volume":"72","author":"Yang","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib27","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1034\/j.1600-0404.2003.00203.x","article-title":"Thalidomide neuropathy: clinical, electrophysiological and neuroradiological features","volume":"109","author":"Isoardo","year":"2004","journal-title":"Acta Neurol Scand"},{"issue":"9140","key":"10.1016\/j.jaad.2015.09.039_bib28","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jaad.2015.09.039_bib29","first-page":"765","article-title":"Frequency of thromboembolic events associated with thalidomide in the non-cancer setting: a case report and review of the literature","volume":"8","author":"Fabi","year":"2009","journal-title":"J Drugs Dermatol"},{"issue":"7","key":"10.1016\/j.jaad.2015.09.039_bib30","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1111\/j.1365-2230.2009.03345.x","article-title":"Thalidomide-induced polyneuropathy: friend or\u00a0foe for relief of itch?","volume":"34","author":"Lin","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib31","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.jpainsymman.2014.06.001","article-title":"Thalidomide therapy for pruritus in the palliative setting\u2013a distinct subset of patients in whom the benefit may outweigh the risk","volume":"48","author":"Lowney","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"10.1016\/j.jaad.2015.09.039_bib32","first-page":"814","article-title":"Thalidomide and analogues: potential for immunomodulation of inflammatory and neoplastic dermatologic disorders","volume":"9","author":"Ladizinski","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2015.09.039_bib33","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/j.1365-2133.2005.06492.x","article-title":"Thalidomide in the management of epidermolysis bullosa pruriginosa","volume":"152","author":"Ozanic Bulic","year":"2005","journal-title":"Br J Dermatol"},{"issue":"9423","key":"10.1016\/j.jaad.2015.09.039_bib34","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib35","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1046\/j.1523-1747.1999.00744.x","article-title":"Thalidomide increases human keratinocyte migration and proliferation","volume":"113","author":"Nasca","year":"1999","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib36","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.4049\/jimmunol.172.3.1848","article-title":"The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process","volume":"172","author":"Ishida","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2015.09.039_bib37","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.neuint.2015.04.006","article-title":"Involvement of peripheral TRPV1 channels in the analgesic effects of thalidomide","volume":"85-86","author":"Song","year":"2015","journal-title":"Neurochem Int"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib38","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.ejphar.2006.02.051","article-title":"Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation","volume":"536","author":"Vale","year":"2006","journal-title":"Eur J Pharmacol"},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1365-4362.1973.tb00066.x","article-title":"Thalidomide in the treatment of actinic prurigo","volume":"12","author":"Londono","year":"1973","journal-title":"Int J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib40","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0168-8278(94)80092-8","article-title":"Thalidomide as therapy for primary biliary cirrhosis: a double-blind placebo controlled pilot study","volume":"21","author":"McCormick","year":"1994","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.jaad.2015.09.039_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1080\/000155500750012450","article-title":"Antipruritic action of thalidomide","volume":"80","author":"Daly","year":"2000","journal-title":"Acta Derm Venereol"},{"issue":"7","key":"10.1016\/j.jaad.2015.09.039_bib42","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1001\/archderm.140.7.845","article-title":"Thalidomide treatment for prurigo nodularis in human immunodeficiency virus-infected subjects: efficacy and risk of neuropathy","volume":"140","author":"Maurer","year":"2004","journal-title":"Arch Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib43","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/j.1346-8138.2007.00260.x","article-title":"Treatment of idiopathic prurigo nodularis in Taiwanese patients with low-dose thalidomide","volume":"34","author":"Lan","year":"2007","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib44","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000245988","article-title":"Sequential combined therapy with thalidomide and narrow-band (TL01) UVB in the treatment of prurigo nodularis","volume":"195","author":"Ferrandiz","year":"1997","journal-title":"Dermatology"},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib45","doi-asserted-by":"crossref","first-page":"412","DOI":"10.2340\/0001555564412417","article-title":"Thalidomide treatment of prurigo nodularis","volume":"64","author":"Winkelmann","year":"1984","journal-title":"Acta Derm Venereol"},{"issue":"38","key":"10.1016\/j.jaad.2015.09.039_bib46","first-page":"3028","article-title":"[Thalidomide treatment of prurigo nodularis]","volume":"155","author":"Johnke","year":"1993","journal-title":"Ugeskr Laeger"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1046\/j.1440-0960.2002.00593.x","article-title":"Thalidomide experience of a major Australian teaching hospital","volume":"43","author":"Crouch","year":"2002","journal-title":"Australas J Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib48","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000331577","article-title":"Thalidomide in 42 patients with prurigo nodularis Hyde","volume":"223","author":"Andersen","year":"2011","journal-title":"Dermatology"},{"issue":"6","key":"10.1016\/j.jaad.2015.09.039_bib49","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.anai.2014.09.010","article-title":"Prurigo nodularis and Hashimoto thyroiditis","volume":"113","author":"Rishi","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"7","key":"10.1016\/j.jaad.2015.09.039_bib50","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archdermatol.2011.2918","article-title":"Treatment of refractory prurigo nodularis with lenalidomide","volume":"148","author":"Kanavy","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib51","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1046\/j.1365-4362.2003.01184.x","article-title":"Treatment of prurigo nodularis with thalidomide: a case report and review of the literature","volume":"42","author":"Alfadley","year":"2003","journal-title":"Int J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2015.09.039_bib52","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1001\/archderm.1980.01640290081018","article-title":"Treatment of prurigo nodularis with thalidomide","volume":"116","author":"van den Broek","year":"1980","journal-title":"Arch Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib53","first-page":"141","article-title":"Prurigo nodularis of Hyde treated with low-dose thalidomide","volume":"13","author":"Orlando","year":"2009","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"42","key":"10.1016\/j.jaad.2015.09.039_bib54","first-page":"3243","article-title":"[Treatment of prurigo nodularis Hyde with thalidomide]","volume":"145","author":"Hoyer","year":"1983","journal-title":"Ugeskr Laeger"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib55","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1159\/000187978","article-title":"Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial","volume":"67","author":"Silva","year":"1994","journal-title":"Nephron"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib56","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1111\/bjh.12265","article-title":"Thalidomide in\u00a0systemic mastocytosis: results\u00a0from an open-label, multicenter, phase II study","volume":"161","author":"Gruson","year":"2013","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.jaad.2015.09.039_bib57","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2230.2008.03046.x","article-title":"Treatment of cutaneous lichen planus with thalidomide","volume":"34","author":"Moura","year":"2009","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib58","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1365-2133.1983.tb04601.x","article-title":"Thalidomide in actinic prurigo","volume":"108","author":"Lovell","year":"1983","journal-title":"Br J Dermatol"},{"issue":"14","key":"10.1016\/j.jaad.2015.09.039_bib59","first-page":"1158","article-title":"[Actinic prurigo]","volume":"170","author":"Stockbridge","year":"2008","journal-title":"Ugeskr Laeger"},{"issue":"4","key":"10.1016\/j.jaad.2015.09.039_bib60","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2230.1977.tb01577.x","article-title":"Actinic prurigo (Hutchinson's summer prurigo)","volume":"2","author":"Calnan","year":"1977","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2015.09.039_bib61","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1067\/moe.2002.123539","article-title":"Actinic prurigo cheilitis: clinicopathologic analysis and therapeutic results in 116 cases","volume":"94","author":"Vega-Memije","year":"2002","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"issue":"1","key":"10.1016\/j.jaad.2015.09.039_bib62","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dth.12047","article-title":"Epidermolysis bullosa pruriginosa showing good response to low-dose thalidomide\u2013a report of two cases","volume":"27","author":"Ranugha","year":"2014","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib63","doi-asserted-by":"crossref","first-page":"201","DOI":"10.47276\/lr.85.3.201","article-title":"Annular bullous lesions with atypical erythema multiforme in leprosy","volume":"85","author":"Shah","year":"2014","journal-title":"Lepr Rev"},{"issue":"7","key":"10.1016\/j.jaad.2015.09.039_bib64","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/1049909110362523","article-title":"Thalidomide for the control of severe paraneoplastic pruritus associated with Hodgkin's disease","volume":"27","author":"Goncalves","year":"2010","journal-title":"Am J Hosp Palliat Care"},{"issue":"3","key":"10.1016\/j.jaad.2015.09.039_bib65","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000370302","article-title":"Angioimmunoblastic T-cell lymphoma: a diagnostic challenge","volume":"6","author":"Ocampo-Garza","year":"2014","journal-title":"Case Rep Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2015.09.039_bib66","first-page":"1140","article-title":"[Schnitzler syndrome\u2013report on a fourteen-year course of the disease and an overview of information on the disease]","volume":"54","author":"Adam","year":"2008","journal-title":"Vnitr Lek"},{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.2310\/7750.2006.00017","article-title":"Urticaria as a cutaneous sign of adult-onset Still's disease","volume":"10","author":"Criado","year":"2006","journal-title":"J Cutan Med Surg"},{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib68","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1007\/s12185-010-0752-0","article-title":"FGF-R3 and OPG expression in patient with multiple myeloma following systemic sclerosis: case report and review of the literature","volume":"93","author":"Colovic","year":"2011","journal-title":"Int J Hematol"},{"issue":"830","key":"10.1016\/j.jaad.2015.09.039_bib69","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1136\/pgmj.70.830.901","article-title":"Guideline for the clinical use and dispensing of thalidomide","volume":"70","author":"Powell","year":"1994","journal-title":"Postgrad Med J"},{"issue":"2","key":"10.1016\/j.jaad.2015.09.039_bib70","doi-asserted-by":"crossref","first-page":"213","DOI":"10.4103\/0019-5154.152580","article-title":"Thalidomide in dermatology: revisited","volume":"60","author":"Hassan","year":"2015","journal-title":"Indian J Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215022379?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215022379?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:37:49Z","timestamp":1759271869000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215022379"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0190962215022379"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.09.039","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide for the treatment of chronic refractory pruritus","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.09.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}